VVUS: VIVUS INC. (NASDAQ) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VVUS: VIVUS INC. (NASDAQ)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Zebra 365 who wrote (9217)	6/5/1998 9:21:00 AM
From: Frostman	Read Replies (1) of 23519

Zebra, WSJ interactive picked up the story this morning as well.. ************************ Vivus: Efficacy Of Muse Impotence Pdt Is 'Dose Dependent' Dow Jones Newswires MOUNTAIN VIEW, Calif. -- Vivus Inc. (VVUS) said the efficacy of its impotence drug, Muse, is "dose dependent." The company was responding to recent media reports about "disappointing results" presented by Dallas researchers at the American Urological Association annual meeting earlier this week. In a press release Friday, Vivus said the data, which indicated that 27% of patients achieved rigidity sufficient for intercourse, were based on a study in which not all men were challenged to the highest doses (500 or 1,000 mcg) of Muse. The company said only 9% of the patients in the study received the 1,000-mcg dose. Vivus said in its own trials, between 41% and 65% of men required the 1,000-mcg dose to achieve rigidity sufficient for intercourse....>> etc etc. *****************************

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next